| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Firefly Neuroscience, Inc.$1.17
-0.01 (-0.84%)
Market Cap
18.26 M
EPS
-0.57
P/E Ratio
-
Value Trade
596.37 K
SEC Financials
Q1 2026Dilution Risk
Revenue
485.00 K
R&D Expenses
424.00 K
Operating CF
-1.95 M
Total Assets
10.91 M
Total Liabilities
2.47 M
Equity
8.44 M
7.48 %
Week
-10.16 %
1 Month
-40.41 %
3 Month
50.46 %
6 Month
-97.46 %
5 Year
-86.87 %
All Time
Cash Data
Cash Position
3.13 M
Monthly Burn
649.00 K
Runway
2 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
843.92 K
52 Week Range
0.62 - 3.63
% held by Insiders
14.24 %
% held by Institutions
7.71 %
Enterprise Value
14.53 M
Total Shares
15.61 M
Short %
5.02 %
Float Shares
13.05 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BMB-101 | neuropsychiatric disorders | Phase 1 | 2024-10-16 | positive topline findings from our recently completed Phase 1 study of BMB-101 Read More | Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology Read More | |
BMB-101 | neuropsychiatric disorders | Phase 1 | 2024-10-16 | positive topline findings from our recently completed Phase 1 study of BMB-101 Read More | Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology Read More | |
BMB-101 | neuropsychiatric disorders | Phase 1 | 2024-10-16 | positive topline findings from our recently completed Phase 1 study of BMB-101 Read More | Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AIFF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AIFF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AIFF▼ -0.8%today
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience reported a remarkable 291% increase in clinical assessments at TMS centers using its FDA-cleared Evoke™ platform. This AI-powered EEG/ERP system enhances the understanding of brain activity, enabling clinicians to tailor treatments for conditions like depression and anxiety. The CEO emphasized the importance of individualized treatment decisions based on objective brain data.
Read more →AIFF▼ -6.4%on this news
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
Firefly Neuroscience and Next Health have launched a precision cognitive health initiative following an FDA Advisory Committee's recommendation to ease restrictions on certain neuroprotective peptides. This collaboration aims to integrate AI-driven brain biomarker technology with personalized peptide protocols, potentially enhancing cognitive therapies. However, the recommendation is non-binding and further FDA actions are required for implementation.
Read more →AIFFFirefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
Firefly Neuroscience has announced the discovery of a novel electrophysiological biomarker for PTSD using its FDA-cleared Evoke System. This breakthrough follows a partnership with the U.S. Department of War, aimed at improving assessments for military personnel suffering from PTSD. The discovery leverages advanced AI technology to analyze EEG data, potentially transforming diagnostic and treatment approaches for PTSD.
Read more →AIFF▲ +6%on this news
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository
Firefly Neuroscience has reached a significant milestone by surpassing 200,000 EEG/ERP brain scans, driven by a sequential growth of 5% to 17% over the past four quarters. This achievement supports their goal of creating the first EEG/ERP-based foundation model of the human brain, enhancing capabilities for cognitive biomarker discovery. The company aims to improve diagnostic methods for neurological disorders using advanced AI technologies.
Read more →AIFF▲ +79.8%on this news
Firefly Confirms Public-Private Partnership with the Department of War
Firefly Neuroscience has announced a partnership with the Department of War to utilize its FDA-cleared EEG/ERP technology for assessing and treating PTSD and TBI in U.S. service members. This collaboration aims to fill a gap in military mental health care by providing objective diagnostic tools. The partnership is expected to expand Firefly's presence in the government and defense health sectors.
Read more →AIFF▲ +58%on this news
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
Firefly Neuroscience has announced a significant advancement in identifying ADHD subtypes using AI-powered EEG technology. This breakthrough could enhance clinical diagnosis by providing objective biomarkers, potentially leading to more personalized treatment plans. The company aims to build the world's first EEG/ERP brain foundation model, leveraging a vast repository of brain scans to improve outcomes for ADHD patients.
Read more →AIFF▲ +126.3%on this news· ran to +144% by day 3
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
Firefly Neuroscience, Inc. has reported significant growth, including a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes. The company has partnered with 99 commercial users, completing over 10,800 brain scans. Firefly aims to leverage AI and advanced GPU technology to enhance brain health outcomes and develop a foundation model of the human brain.
Read more →AIFF▲ +5.5%on this news
Firefly Neuroscience Reports Third Quarter 2025 Financial Results
Firefly Neuroscience reported strong financial results for Q3 2025, with revenues increasing over tenfold year-over-year to $388,000, driven by the acquisition of Evoke Neuroscience. The company also achieved a 30% sequential revenue growth from the previous quarter. Operating expenses decreased significantly, contributing to an improved net loss of $2.6 million. Firefly aims to continue its commercial growth strategy while leveraging advanced AI technologies.
Read more →AIFFFirefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America
Firefly Neuroscience has partnered with HealingMaps to provide cognitive electrophysiology analytics to over 2,500 clinics across North America. This collaboration aims to enhance treatment outcomes for patients using ketamine, psilocybin, and TMS therapies by utilizing Firefly's FDA-cleared EEG-based analytics platform. The partnership is expected to empower clinics with objective data and new revenue opportunities.
Read more →AIFFFirefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform
Firefly Neuroscience has launched its new CLEAR Platform, utilizing NVIDIA's L40S GPU to enhance EEG data quality and processing speed. This innovative technology aims to improve brain health outcomes for patients with neurological disorders by enabling more accurate detection of neural biomarkers. The platform represents a significant advancement in clinical insights and supports Firefly's mission in neuroscience.
Read more →AIFF▼ -6%on this news
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research
Firefly Neuroscience has entered a collaboration with Heidelberg University Hospital to study the neurophysiological effects of 15q13.3 copy number variants using its FDA-cleared BNA platform. The study will analyze EEG data from 30 subjects and aims to provide insights into cognitive disorders. This partnership underscores Firefly's commitment to advancing precision neuroscience and enhancing diagnostic methods.
Read more →AIFFFirefly Neuroscience to be Added to the Russell Microcap® Index
Firefly Neuroscience, an AI company focused on brain health, will join the Russell Microcap Index effective June 30, 2025. This inclusion marks a significant milestone for the company, reflecting its progress since its Nasdaq listing. CEO Greg Lipschitz highlighted recent achievements, including advancements in cognitive biomarkers and expansion of their technology platform. The membership is expected to enhance visibility among investors.
Read more →AIFF▼ -8.7%on this newsshared move
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
Firefly Neuroscience has made significant advancements in the objective measurement of subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients. Their study demonstrates that combining EEG/ERP and volumetric MRI can achieve up to 87% accuracy in diagnosing these conditions. This approach promises to enhance early detection and intervention, leveraging Firefly's proprietary technology and extensive database.
Read more →AIFF▼ -9.9%on this news
Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience has announced the acquisition of Evoke Neuroscience, significantly expanding its database, intellectual property portfolio, and commercial footprint. This acquisition is a strategic move to enhance Firefly's proprietary Brain Network Analytics technology, aimed at improving brain health outcomes. The deal is expected to facilitate rapid growth and innovation within the company.
Read more →AIFFFirefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
Firefly Neuroscience has acquired Evoke Neuroscience, enhancing its database and intellectual property portfolio. This acquisition is expected to significantly expand Firefly's capabilities in developing a foundation model of the human brain. The deal reflects a strategic move to leverage technological synergies and improve brain health outcomes for patients with neurological disorders.
Read more →AIFF▲ +8.2%on this news· ran to -26% by day 3
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Firefly Neuroscience has successfully exercised warrants, raising $8.8 million to support its initiatives. The funds will be allocated towards the development of its FDA-cleared Brain Network Analytics technology, aimed at improving brain health outcomes. The company expresses gratitude towards shareholders for their confidence, highlighting a robust cash position extending into mid-2026.
Read more →AIFF▲ +171%on this news· ran to +318% by day 1
Firefly Neuroscience Accepted into NVIDIA Connect Program
Firefly Neuroscience has been accepted into the NVIDIA Connect program, which will provide technical resources to enhance its FDA-cleared Brain Network Analytics (BNA™) platform. The company aims to develop the world's first foundation model of the human brain using its innovative technology. Firefly's BNA™ technology is designed to improve diagnostic and treatment methods for various neurological and mental disorders.
Read more →AIFFFirefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
Firefly Neuroscience congratulates Dr. Christopher Wilson for receiving the Faculty Research Excellence Award from the University of Waterloo's Faculty of Engineering. Dr. Wilson, a prominent figure in superconducting quantum electronics, has significantly contributed to the field, securing substantial research funding and supervising numerous students. Firefly acknowledges his role on the Advisory Development Board and looks forward to his collaboration on an upcoming brain model initiative. The company continues to advance its FDA-cleared Brain Network Analytics technology aimed at enhancing diagnostic and treatment monitoring for neurological and mental disorders.
Read more →AIFF▲ +12.3%on this news
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care
Firefly Neuroscience has announced two studies highlighting the effectiveness of their BNA™ platform in evaluating drug efficacy and cognitive changes in neuropsychiatric care. The first study shows promising results in assessing MIJ821, a drug from Novartis, using EEG to gauge its antidepressant effects. The second study demonstrates the potential of EEG in tracking cognitive improvements in patients with major depressive disorder. Firefly aims to advance personalized psychiatry and improve treatment outcomes through its innovative technology.
Read more →AIFF▲ +65.8%on this news
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Firefly Neuroscience has announced a significant advancement in its research by discovering a cognitive brain age biomarker via its FDA-cleared BNA™ platform. This innovation utilizes EEG data to evaluate the biological age of the brain, which may serve as a key risk factor for conditions like dementia. The company aims to launch this technology commercially, focusing on its application in drug research and clinical practice, thereby enhancing early screening methods for Alzheimer's disease. Overall, this development highlights Firefly's commitment to improving brain health outcomes through innovative technology.
Read more →AIFFFirefly Neuroscience Closes on Financing of up to $12.4 Million
Firefly Neuroscience has closed a financing deal worth up to $12.4 million, which includes $2.4 million in secured convertible notes. The funding aims to support the commercialization of its Brain Network Analytics (BNA™) technology, which has received FDA clearance. Firefly plans to leverage this capital for growth and to collaborate with neuroscience pharmaceutical companies. The announcement emphasizes the company's commitment to improving brain health outcomes for patients suffering from various neurological and mental disorders.
Read more →AIFFFirefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman
Firefly Neuroscience has appointed Greg Lipschitz as the new Executive Chairman, effective December 3, 2024. Mr. Lipschitz, who has been a board member since December 2022, brings over 13 years of experience in finance and capital markets. His leadership comes at a crucial time as Firefly prepares to commercialize its brain health technology, the Brain Network Analytics (BNA™). This transition follows the resignation of former Executive Chairman David Johnson, who left amicably and was thanked for his contributions.
Read more →AIFF▼ -6.5%on this news
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Firefly Neuroscience, Inc. has reported its third quarter financial results for 2024, highlighting a successful listing on Nasdaq and a strong dual go-to-market strategy. The company has established partnerships with notable pharmaceutical companies to enhance drug development and optimize neurological patient care. Firefly's Brain Network Analytics (BNA™) technology is set for commercial launch, with positive implications for diagnosing and treating various neurological disorders. The company's financial status includes $1.2 million in cash as of September 30, 2024.
Read more →AIFFFirefly Neuroscience to Participate in the 8th Annual Florida Capital Event
Firefly Neuroscience, Inc. (NASDAQ: AIFF) announced its participation in the 8th Annual Florida Capital Event, set for November 22-24, 2024, at the JW Marriott Miami. The company is recognized for its innovative AI-driven Brain Network Analytics (BNA™) technology aimed at improving brain health outcomes for patients with neurological disorders. Firefly's BNA™ has recently received FDA clearance and is now being launched commercially, targeting both pharmaceutical companies and medical practitioners. The Capital Event provides a platform for investors to engage with Firefly's management for potential partnerships and investment opportunities.
Read more →AIFF▲ +10.4%on this news
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Firefly Neuroscience, Inc. has announced the issuance of 557,885 restricted shares to its Executive Chairman, David Johnson, in compliance with Nasdaq Listing Rule 5635(c)(4). This grant is part of the company's Long-Term Incentive Plan and will vest over a one-year period. Firefly focuses on improving brain health through its AI-driven diagnostic technology, Brain Network Analytics. However, the company faces risks related to its technology development and the ongoing merger with WaveDancer, Inc.
Read more →AIFF▲ +31%on this news
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
Firefly Neuroscience, Inc. announced a collaboration with Bright Minds Biosciences to analyze data from its positive Phase 1 study of BMB-101. The study's qEEG results suggest that BMB-101 effectively penetrates the brain and activates target receptors. This successful outcome positions BMB-101 as ready for Phase 2 trials, reflecting significant advancements in treating neuropsychiatric disorders. Both companies aim to enhance their capabilities in clinical research, leveraging AI and advanced EEG analysis technologies.
Read more →AIFFFirefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder
Firefly Neuroscience announced the use of its Brain Network Analytics platform in a Phase 1 study of SP-624, aiming to treat women with Major Depressive Disorder (MDD). The study is designed to assess the drug's impact on cognitive functions and neurological pathways, focusing on epigenetic mechanisms. Initial results from prior studies show statistically significant improvements with SP-624 in female patients but limited efficacy in males. This collaboration aligns with the growing need for targeted treatments for MDD, particularly among women.
Read more →AIFFFirefly Neuroscience to Participate in Upcoming October Investor Conferences
Firefly Neuroscience, Inc. (NASDAQ: AIFF) has announced its participation in two investor conferences in October 2024, aimed at enhancing investor engagement. The company will present its FDA-cleared Brain Network Analytics technology, which is designed to improve brain health outcomes for patients with neurological and mental disorders. This event represents an opportunity for Firefly to showcase its innovative solutions and attract potential investors and partnerships within the healthcare industry. The conferences will include a fireside chat format and are set to take place on October 17 and 30.
Read more →AIFF▼ -6%on this news· ran to -22% by day 3
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
Firefly Neuroscience has announced advancements in its AI-driven Brain Network Analytics (BNA™) technology following successful research collaborations with Takeda and Novartis. This development aims to improve drug development processes in neuroscience by providing objective measures of brain activity. Firefly's technology claims to enhance patient and dose selection, thereby reducing costs and accelerating drug development timelines. The company is now commercially launching its BNA™ technology, targeting pharmaceutical companies engaged in drug research and trials.
Read more →AIFFFirefly and Zeto team up to distribute EEG headset devices
Zeto has partnered with Firefly Neuroscience to distribute its FDA-cleared EEG headsets, WR19 and Zeto ONE. Firefly will serve as a non-exclusive distributor, enhancing the reach of these devices. The partnership also involves integrating Firefly's Brain Network Analytics technology with Zeto's EEG platforms, which are already utilized in over 200 healthcare facilities across the U.S.
Read more →AIFFZeto inks partnership with Firefly Neuroscience
Zeto has entered a strategic partnership with Firefly Neuroscience to enhance the distribution of its FDA-cleared EEG headset devices. Firefly will serve as a non-exclusive distributor for Zeto's products. This collaboration will also integrate Firefly's Brain Network Analytics technology with Zeto's EEG platforms, which are already in use at over 200 hospitals and neurology offices nationwide.
Read more →AIFFFirefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Firefly Neuroscience has announced a partnership with Zeto to distribute its FDA-cleared EEG technology alongside Firefly's proprietary Brain Network Analytics (BNA™) technology. This collaboration is intended to improve access to brain monitoring solutions across various healthcare settings. The integration of these technologies aims to provide enhanced insights into neurological conditions, thereby optimizing patient outcomes. Firefly will act as a non-exclusive distributor of Zeto's EEG devices and cloud services, enabling real-time data analysis for healthcare providers.
Read more →AIFFFirefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
Firefly Neuroscience has appointed Dr. Stella Vnook to its Board of Directors, effective August 19, 2024. Dr. Vnook, a seasoned pharmaceutical executive, will also serve as Chairperson of the Nominating Committee. Her extensive experience in biotechnology and life sciences is expected to drive strategic growth and innovation for Firefly. The company is focusing on enhancing their Brain Network Analytics technology for improved diagnosis and treatment monitoring of neurological disorders.
Read more →AIFF▲ +9.6%on this news
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
Firefly Neuroscience CEO Jon Olsen is set to present at H.C. Wainwright's 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. He will highlight key corporate milestones, including the FDA clearance of the Brain Network Analytics (BNA™) platform, which aims to improve brain health outcomes for patients with neurological disorders. Firefly's innovative AI technology is designed to assist clinicians in diagnosing and optimizing treatments for conditions such as depression, dementia, and ADHD. However, the company faces various risks related to the development and commercialization of its technology and the implications of its recent merger with WaveDancer.
Read more →AIFFFirefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
Firefly Neuroscience, Inc. has announced a shareholder update call scheduled for September 4, 2024. The company is focused on developing its FDA-cleared Brain Network Analytics platform, which aims to revolutionize diagnostics and treatment methods for various neurological disorders. Firefly has invested approximately $60 million into this platform, which leverages AI and a proprietary database to improve patient outcomes. The commercial launch of the BNA platform targets both pharmaceutical companies and medical practitioners.
Read more →AIFFFirefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas
Firefly Neuroscience has established a strategic partnership with Neurology Consultants of Dallas. This collaboration aims to enhance early detection and disease management for patients experiencing cognitive decline. The partnership leverages AI technology to improve outcomes for individuals with mental illnesses and neurological disorders.
Read more →AIFF▼ -10%on this newsshared move
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
Firefly Neuroscience has partnered with Neurology Consultants of Dallas to enhance early detection and management of cognitive disorders through the integration of Firefly's Brain Network Analytics technology into NCD's workflow. This partnership aims to improve diagnosis and patient care pathways for conditions such as dementia and Alzheimer's disease. The collaboration is expected to leverage NCD's clinical experience and the innovative capabilities of Firefly's technology, promoting better outcomes for patients with cognitive decline across the U.S.
Read more →AIFF▼ -5.4%on this news
Diagnostics World News Roundup
Firefly Neuroscience has partnered with Neurology Consultants of Dallas to improve early detection and management of cognitive decline. The collaboration will integrate Firefly's Brain Network Analytics technology into clinical workflows, facilitating studies to identify biomarkers for dementia. This initiative aims to establish patient baselines for better tracking of cognitive changes.
Read more →AIFF▼ -18.6%on this newsshared move
AI Medtech Specialist Firefly Lists on Nasdaq after Merger
Firefly Neuroscience has successfully listed on Nasdaq following a $45 million reverse merger with WaveDancer. The newly combined entity will focus on commercializing its FDA-cleared Brain Network Analytics platform. This platform aims to assist neurologists in the US and collaborate with pharmaceutical companies for developing treatments for central nervous system disorders.
Read more →AIFFFirefly Neuroscience Announces Closing of Merger Agreement and is Scheduled to Begin Trading on Nasdaq Under the Ticker Symbol ‘AIFF’ on August 13, 2024
Firefly Neuroscience has successfully closed its merger with WaveDancer, Inc. and will begin trading on Nasdaq under the ticker symbol 'AIFF' starting August 13, 2024. This merger is anticipated to provide enhanced capital for the commercialization of Firefly's AI-driven Brain Network Analytics technology. The company aims to improve diagnosis and treatment for patients with mental illnesses and neurological disorders, with the BNA platform having already conducted over 77,000 brain scans. Additionally, Firefly has completed a private placement offering to secure further funding for operational needs.
Read more →AIFFFirefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer
Firefly Neuroscience has appointed Dr. Samer Kaba, MD, as its Chief Medical Officer. This strategic addition aims to strengthen the company’s leadership as it approaches the conclusion of its merger with WaveDancer, Inc. Dr. Kaba brings over 20 years of experience in drug development and patient management in neurology, expected to enhance Firefly's capabilities in promoting brain health. Firefly is known for its innovative AI-driven BNA platform that operates with high-definition EEG data to improve patient outcomes in mental and neurological disorders.
Read more →AIFFFirefly Neuroscience, an AI-Driven Brain Health Company, Names Brian S. Posner to its Board of Directors, Upon Closing of Its Merger Transaction with WaveDancer
Firefly Neuroscience has appointed Brian S. Posner to its Board of Directors following the closure of its merger with WaveDancer. Posner brings 35 years of management experience in public and private companies, along with a robust background in capital markets and M&A. The merger aims to enhance Firefly's efforts in developing AI-driven solutions for mental illness and neurological disorders, with the company also pursuing commercial launches of its FDA-cleared software platform. Both companies are currently working towards achieving final closing conditions as outlined in the merger agreement.
Read more →AIFFFirefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, David Johnson as Executive Chairman, Upon Closing of Its Merger Transaction with WaveDancer
Firefly Neuroscience has appointed David Johnson as Executive Chairman following its merger with WaveDancer, which has received stockholder approval. Johnson brings extensive healthcare experience that Firefly believes will be crucial for its growth in developing AI-based mental health solutions. The BNA Platform, an innovative tool for diagnosing mental illnesses, is set to enhance treatment approaches and is currently preparing for commercial launch.
Read more →AIFFFireFly Neuroscience Announces Healthcare Science and AI Industry Leader David DeCaprio to Join Board of Directors
Firefly Neuroscience has announced the appointment of David DeCaprio to its Board of Directors, leveraging his extensive experience in AI and healthcare. This move comes as the company prepares for its merger with WaveDancer and subsequent NASDAQ listing. DeCaprio is recognized for his leadership at ClosedLoop.ai and previous involvement in significant projects like the Human Genome Project. Firefly aims to enhance diagnostic and treatment methods for mental illnesses using its FDA-cleared BNA software platform, developed over years of investment and advanced neuroscientific research.
Read more →AIFFFirefly Neuroscience’s White Paper Unveils BNA™ Platform’s Significant Impact on Disease Management in 2,253 U.S Patients
Firefly Neuroscience has released a white paper presenting findings from a study involving 2,253 U.S. patients that analyzed the effectiveness of its Brain Network Analytics (BNA™) Platform in psychiatric treatment. The BNA™ Platform, which utilizes advanced AI to automate EEG analysis, demonstrated significant improvements in treatment compliance, reduction in medication alterations, and enhanced overall patient functionality in conditions like major depressive disorder, generalized anxiety disorder, and ADHD. The CEO emphasized that these findings could lead to transformative changes in disease management and enhance patient outcomes, as well as potential cost savings for healthcare systems. Firefly is in the process of merging with WaveDancer, further indicating its growth and impact in the neuroscience sector.
Read more →AIFFFirefly Neuroscience, Inc. Issues Letter to Stockholders on Proposed Merger with WaveDancer
Firefly Neuroscience, Inc. has issued a letter to its stockholders regarding the proposed merger with WaveDancer, Inc., which is scheduled for a formal approval meeting on March 14, 2024. CEO Jon Olsen emphasized the urgent need for innovative solutions in mental health care, highlighting the capabilities of Firefly's BNA™ Platform, which utilizes AI and EEG data to improve diagnostic accuracy and treatment outcomes. The letter also outlines the company's strategic direction following the merger and acknowledges ongoing support from stockholders. There are risks associated with the merger, including the necessity of stockholder approval and successful integration of both companies.
Read more →AIFFFor additional information contact: Richard S. DeRose (703) 293-7901 For release
additional information contact: release: March 29, 2018 Information Analysis Inc. Reports Profitable Results for VIRGINIA Information Analysis Incorporated. (IAIC:OTCBB) today reported results for the year ended December 31, 2017. Revenues were up 58% to $10,641,000, compare
Read more →AIFFBlueprint For additional information contact: Richard S. DeRose (703) 293-7901 For release
additional information contact: S. DeRose (703) 293-7901 Information Analysis Incorporated Reports Profitable Second Quarter VIRGINIA Information Analysis Incorporated (OTCBB:IAIC) (the Company ) reported results for its second fiscal quarter ended June 30, 2017. Revenues fo
Read more →AIFFFor additional information contact: Sandor Rosenberg (703) 293-7900 For release
For additional information contact: Sandor Rosenberg (703) 293-7900 For release: August 10, 2005 at 9:00 a.m. Analysis, Inc. Reports Second Quarter Results Information Analysis Inc. (OTCBB: IAIC) reported results for the second quarter ended June 30, 2005. Revenues were $3,006,
Read more →Competitive Position
How AIFF ranks across every disease it competes inCompetitive Position is a premium feature
See how AIFF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial